A Comprehensive Monograph on Urea (Carbamide): From Foundational Chemistry to Advanced Therapeutic Applications

Introduction and Historical Context

Executive Summary

This report provides an exhaustive analysis of urea, also known as carbamide, a small organic molecule with profound biological and therapeutic significance. Biologically, urea is the principal end-product of protein catabolism in mammals, synthesized in the liver to detoxify ammonia.[1] Therapeutically, it has evolved into a versatile agent with widespread applications in modern medicine, most notably in dermatology as a moisturizer and keratolytic, in nephrology for the management of hyponatremia, and in diagnostics for detecting bacterial infections.[1] This monograph synthesizes its fundamental physicochemical properties, multifaceted pharmacological actions, pharmacokinetic profile, clinical evidence base, safety considerations, and global regulatory landscape, offering a comprehensive overview of its journey from a metabolic waste product to a cornerstone therapeutic.

Historical Milestone: The Wöhler Synthesis

The scientific journey of urea is inextricably linked to a pivotal moment in the history of chemistry. In 1828, the German chemist Friedrich Wöhler successfully synthesized urea by heating ammonium cyanate, an inorganic compound.[2] This landmark achievement was the first documented laboratory synthesis of a naturally occurring organic compound from purely inorganic starting materials. At the time, the prevailing scientific doctrine was vitalism, which posited that organic compounds—the "chemicals of life"—could only be produced by living organisms through a "vital force".[2] Wöhler's synthesis directly contradicted and ultimately dismantled this theory, demonstrating that the same chemical principles govern both the living and non-living worlds. This experiment is widely regarded as a foundational event that bridged the gap between inorganic and organic chemistry, paving the way for the modern era of chemical synthesis and pharmaceutical development.[2] This historical context establishes urea's unique position at the nexus of biology and chemistry.

Physicochemical Characteristics

Chemical Identity and Nomenclature

Urea is a simple yet structurally significant organic compound. It is chemically known as carbamide, reflecting its structure as the diamide of carbonic acid.[2] Its fundamental identifiers are as follows:

• Molecular Formula: CH4​N2​O, often represented as CO(NH2​)2​.[1]
• Molecular Weight: Approximately 60.06 g/mol.[1]
• Registry Numbers: Its universal identifier is CAS Registry Number 57-13-6. In pharmaceutical and regulatory databases, it is identified as DrugBank ID DB03904, EINECS 200-315-5, and FDA UNII 8W8T17847W.[1]
• Structure: The urea molecule features a central carbonyl group (>C=O) bonded to two amino groups (−NH2​). In its solid crystalline state, the molecule is planar due to the sp2 hybridization of the nitrogen orbitals.[1] This planarity is disrupted in the gas phase or in aqueous solution, where it adopts a non-planar structure with C2​ symmetry.[2] This structural duality is critical to its chemical behavior, influencing its extensive hydrogen bonding with water and its ability to form porous frameworks known as clathrates, which can trap other organic molecules.[2]

Physical Properties

Urea presents as a white, solid, and typically odorless crystalline substance or powder.[1] Its key physical properties are:

• Melting Point: Urea melts in the range of 132–135 °C. It decomposes before reaching its boiling point.[3]
• Density: The density is consistently reported as approximately 1.32–1.335 g/cm³.[1]
• Solubility: It is highly soluble in water, with a solubility of 1080 g/L at 20 °C.[8] This exceptional aqueous solubility is a direct result of its molecular structure, which allows it to engage in extensive hydrogen bonding with water molecules.[2] It is also soluble in polar solvents like methanol, ethanol, and glycerol but is poorly soluble in nonpolar organic solvents such as chloroform and benzene.[9]
• pH: In aqueous solution, urea is practically neutral. A 10% solution has a pH of approximately 7.2, while a more concentrated 8M solution exhibits a slightly alkaline pH of 8.0-10.0.[8]

Chemical Properties, Stability, and Formulation Considerations

The chemical behavior of urea dictates both its therapeutic utility and the requirements for its formulation and storage.

• Hygroscopicity: Urea is highly hygroscopic, meaning it readily absorbs moisture from the atmosphere.[6] This chemical property is the very basis for its function as a humectant in dermatological products. However, this same characteristic presents a significant challenge from a pharmaceutical standpoint. If not stored in moisture-protected, tightly sealed containers, urea powder will absorb water, leading to physical clumping and potential chemical degradation, which can compromise the product's stability and efficacy.[6] This direct link between its primary mechanism of action and its stability profile means that the choice of packaging and the formulation's vehicle (e.g., an occlusive ointment versus a water-based cream) are critical technical considerations for maintaining the drug's potency.
• Thermal Decomposition: When heated above its melting point, urea undergoes decomposition. Above 160 °C, it breaks down into ammonia (NH3​) and isocyanic acid (HNCO). The isocyanic acid can further react with urea to form condensation products such as biuret and triuret.[2] This thermal instability is a key consideration in manufacturing processes and storage conditions.
• Reactivity: Urea is a very weak base (pKb 13.9) and reacts with strong acids to form uronium salts.[2] It must be stored away from strong oxidizing agents, such as hypochlorites, with which it can react to form the explosive compound nitrogen trichloride.[10] In aqueous solutions, urea exists in a slow equilibrium with ammonium cyanate. The resulting isocyanic acid can carbamylate proteins, a reaction of particular importance in laboratory settings like proteomics where high concentrations of urea are used as a protein denaturant.[2]
• Storage: To ensure stability, urea should be protected from moisture.[10] Recommended storage temperatures range from room temperature to refrigerated conditions (2-8 °C), often in a cool, dark place.[8]

Table 1: Summary of Key Physicochemical Properties of Urea

Property	Value
IUPAC Name	Urea
Synonyms	Carbamide, Carbonyldiamide, Ureophil 1
Molecular Formula	CH4​N2​O 1
Molecular Weight	60.06 g/mol 1
CAS Number	57-13-6 [User Query]
DrugBank ID	DB03904 [User Query]
Appearance	White, odorless, crystalline solid/powder 1
Melting Point	132-135 °C (decomposes) 8
Density	1.32-1.335 g/cm³ 1
Water Solubility	1080 g/L (at 20 °C) 8
pKa	0.10 (at 25 °C) 8
LogP	-1.66 (estimated) 8

Pharmacology and Mechanisms of Action

Urea exhibits distinct pharmacological actions depending on its route of administration and concentration, functioning as a sophisticated dermatological agent topically and as an osmotic agent systemically.

A. Dermatological and Topical Mechanisms: A Multi-faceted Approach to Skin Health

The therapeutic effects of topical urea are concentration-dependent and involve a combination of physicochemical and biological actions.

• Humectant and Moisturizing Effects (Low Concentrations, ≤10%): At lower concentrations, urea's primary role is to hydrate the skin. It is a key component of the skin's own Natural Moisturizing Factor (NMF), which is crucial for maintaining the hydration and integrity of the stratum corneum.[14] As a powerful hygroscopic molecule, it acts as a humectant, drawing water from the deeper dermal layers and the external environment into the epidermis. This action increases the water-binding capacity of the stratum corneum, enhances water retention, and reduces transepidermal water loss (TEWL).[14]
• Keratolytic and Proteolytic Action (High Concentrations, >10%): As the concentration increases above 10%, urea's keratolytic properties become prominent.[15] It functions by gently dissolving the intracellular matrix of the stratum corneum. This is achieved by denaturing keratin and breaking the hydrogen bonds within the protein's structure, which leads to a loosening of the horny layer of the skin.[14] This effect promotes the desquamation (shedding) of scaly, hyperkeratotic skin, making it an effective treatment for conditions characterized by skin thickening.[21] At very high concentrations, typically 40% or more, its action becomes proteolytic, meaning it can break down proteins more extensively. This potent effect is harnessed for the non-surgical debridement or avulsion of dystrophic nails.[18]
• Skin Barrier Enhancement and Gene Regulation: The mechanism of urea extends beyond simple hydration and exfoliation. It functions as an active biological signaling molecule that modulates cellular processes in the epidermis. Research has shown that urea regulates gene expression in keratinocytes, upregulating genes that are critical for proper skin barrier function and differentiation, such as filaggrin, loricrin, and transglutaminase-1.[14] This represents a significant paradigm shift in understanding its function; urea is not merely a passive moisturizer but an active agent that stimulates the skin to repair its own barrier. Furthermore, it enhances the skin's innate antimicrobial defense system by increasing the expression of antimicrobial peptides (AMPs), including cathelicidin and β-defensin-2.[14] This dual-action—providing immediate hydration while simultaneously signaling the skin to produce its own moisturizing and defense components—explains its profound efficacy in complex dermatoses like atopic dermatitis, which involve both barrier defects and microbial imbalances.
• Penetration Enhancement: By hydrating the stratum corneum and disrupting its keratin structure, urea increases the permeability of the skin. This action facilitates the penetration and transport of other co-administered topical drugs, such as corticosteroids and antifungal agents, through the skin and into the nail plate, thereby enhancing their therapeutic effect.[14]

B. Systemic Mechanisms of Action

When administered systemically, urea's primary mechanism of action is based on its osmotic properties.

• Osmotic Diuresis: Systemic urea functions as an effective osmotic diuretic.[25] After administration, it is freely filtered by the glomerulus into the renal tubules. Because it undergoes only limited reabsorption, it remains within the tubular fluid, significantly increasing the filtrate's osmolarity, particularly in the proximal tubule and the loop of Henle.[25] This high osmotic pressure opposes the normal reabsorption of water, leading to diuresis. This process, known as aquaresis, primarily promotes the excretion of solute-free water, having a lesser effect on electrolyte excretion compared to other diuretic classes.[25]
• Reduction of Intracranial and Intraocular Pressure (Historical Use): This therapeutic application was a direct result of urea's osmotic effect on body fluid compartments. When administered intravenously, urea transiently raises the osmolarity of the blood.[25] Because urea does not readily cross the intact blood-brain and blood-ocular barriers, it establishes an osmotic gradient that effectively pulls water from the brain parenchyma and intraocular fluid into the intravascular space. This fluid shift reduces the volume of these compartments, thereby lowering intracranial and intraocular pressure.[25]
• Correction of Hyponatremia (Modern Use): In disease states characterized by inappropriate water retention, such as the Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH), the body has an excess of water relative to sodium, leading to dilutional hyponatremia. Oral urea corrects this imbalance by inducing osmotic diuresis, which promotes the excretion of excess free water.[27] This action increases the serum sodium concentration by removing water, thereby normalizing the sodium-to-water ratio without causing significant depletion of essential electrolytes.[33]

Pharmacokinetics: The Journey of Endogenous and Exogenous Urea

Endogenous Production and Homeostasis

Urea is the primary nitrogenous waste product resulting from protein and amino acid metabolism in mammals. It is synthesized almost exclusively in the liver through the urea cycle, a critical metabolic pathway that converts highly toxic ammonia into the much less toxic and highly soluble urea for excretion.[1] The rate of endogenous urea production is dynamic, increasing with high dietary protein intake, in hypercatabolic states such as fever or infection, or during gastrointestinal bleeding. Conversely, production decreases with a low-protein diet or in cases of severe liver dysfunction.[35] A healthy adult consuming a typical Western diet produces approximately 12 grams of urea each day.[35]

Pharmacokinetic Profile of Exogenous Urea (ADME)

When administered as a drug, urea follows a predictable pharmacokinetic pathway.

• Absorption: Following oral administration, urea is readily absorbed from the gastrointestinal tract.[36] Pharmacokinetic studies in rats have demonstrated linear pharmacokinetics over a wide dose range, with peak plasma concentrations ( Cmax​) achieved between 0.5 and 1 hour post-administration. The oral bioavailability in this model was estimated to be approximately 74%.[37]
• Distribution: As a small, uncharged, and highly polar molecule, urea distributes extensively throughout the total body water.[35] Animal studies confirm this wide distribution, with the highest tissue concentrations found in the kidneys, consistent with its primary route of elimination.[37]
• Metabolism: Urea is a terminal metabolic product and does not undergo further metabolism by human enzymes. However, a portion of both endogenous and exogenous urea is subject to an enterohepatic recycling pathway. In the gut, particularly the colon, it can be hydrolyzed back into ammonia and carbon dioxide by the urease enzymes of the resident microflora.[35] This process is evidenced by studies in rats where, after an oral dose of radiolabeled urea, a substantial portion (42.9%) was excreted as labeled CO2​ in expired air.[37] This suggests that the gut microbiome can play a surprisingly significant role in the first-pass disposition of orally administered urea. This metabolic activity by gut bacteria could influence the systemic bioavailability of an oral dose, introducing a potential source of inter-patient variability based on the composition and health of an individual's microbiome. This interaction represents a largely uncredited factor in urea's pharmacokinetics and a potential area for future clinical investigation.
• Excretion: The vast majority of urea is cleared from the body by the kidneys.[3] The process begins with free filtration at the glomerulus. As the filtrate passes through the renal tubules, a significant portion of the filtered urea—between 40% and 60%, depending on urine flow rate—is passively reabsorbed back into the bloodstream.[35] The net result is the excretion of about 10 grams of urea per day in a healthy adult.[35] Rat studies show that within 96 hours of an oral dose, approximately 54% is recovered in the urine and only 1% in the feces.[37]

Clinical Applications and Therapeutic Landscape

Urea's diverse mechanisms of action have led to its application across a broad spectrum of clinical settings, from routine dermatological care to specialized hospital-based treatments.

A. Dermatological Therapeutics

In dermatology, urea is a foundational therapeutic agent for conditions involving defects in skin hydration and keratinization.

• Core Indications: It is a first-line treatment for a wide range of hyperkeratotic and xerotic (dry skin) conditions.[15] Its efficacy is well-established for atopic dermatitis (eczema), psoriasis, xerosis (abnormally dry skin), ichthyosis (a group of genetic skin disorders characterized by dry, scaly skin), keratosis pilaris, and keratoderma (thickening of the skin on the palms and soles).[14] Numerous clinical trials have confirmed its ability to improve skin barrier function, increase hydration, and reduce scaling in these patient populations.[14]
• Podiatry and Nail Care: High-concentration formulations, typically 40% to 50%, are widely used in podiatry for the management of thick calluses and corns. These preparations are also the standard of care for the chemical, non-surgical debridement of dystrophic (malformed) or damaged nails, which is often necessary in the treatment of onychomycosis (fungal nail infection) to remove the diseased nail plate and improve the penetration of antifungal agents.[15]
• Wound Care: Building on its historical use for its proteolytic and antibacterial properties, urea remains relevant in wound care.[16] It is often included in debriding ointments, frequently in combination with enzymes like papain, to help break down and remove necrotic tissue, eschar, and fibrinous debris from wounds, thereby promoting a healthier wound bed and facilitating healing.[38]

Table 2: Concentration-Dependent Topical Applications and Formulations of Urea

Urea Concentration Range	Primary Pharmacological Effect	Key Clinical Applications
2% – 10%	Moisturizing / Humectant	Xerosis (dry skin), atopic dermatitis, routine skin hydration, ichthyosis 16
10% – 30%	Keratolytic & Moisturizing	Psoriasis, severe xerosis, keratosis pilaris, calluses, eczema 16
≥ 40%	Proteolytic / Debriding	Non-surgical avulsion of dystrophic or damaged nails, severe hyperkeratosis, corns 18

B. Systemic Therapeutics

The systemic use of urea has evolved significantly over time, shifting from acute neurological care to the management of electrolyte disorders.

• Management of Hyponatremia: Oral urea has seen a resurgence in clinical use and is now increasingly recognized as a safe, effective, and notably cost-effective treatment for euvolemic and hypervolemic hyponatremia, particularly when caused by SIADH.[32] A growing body of evidence from observational studies and meta-analyses demonstrates that oral urea significantly increases serum sodium levels, with a low risk of dangerously rapid overcorrection.[32] Its efficacy is considered comparable to that of fluid restriction or more expensive vaptan drugs and superior to no treatment.[45]
• Reduction of Intracranial Pressure (Historical): From the 1950s through the early 1970s, intravenous urea was a standard-of-care agent for the emergency reduction of cerebral edema and elevated intracranial pressure (ICP).[28] While effective, it was eventually superseded by mannitol, which was found to have a more favorable side-effect profile, particularly a lower incidence of rebound intracranial hypertension—a phenomenon where ICP rises again, sometimes to levels higher than baseline, after the drug's effect wears off.[28]

C. Diagnostic Applications

Urea's role in specific metabolic pathways has been leveraged for diagnostic purposes.

• Helicobacter pylori Detection: The Urea Breath Test (UBT) is a highly accurate, non-invasive method for diagnosing H. pylori infection, a primary cause of peptic ulcers. The test involves the patient ingesting a small amount of urea labeled with a non-radioactive (13C) or radioactive (14C) carbon isotope. If H. pylori is present in the stomach, its potent urease enzyme rapidly hydrolyzes the labeled urea into ammonia and labeled carbon dioxide (CO2​). This labeled CO2​ is absorbed into the bloodstream, travels to the lungs, and is detected in the patient's exhaled breath.[48] The FDA approved the PyloPlus UBT System for this use in 2020.[51]
• Oncology Imaging (Investigational): Urea has been evaluated in several clinical trials as a component of diagnostic agents for prostate cancer imaging. It has been used in Phase 0, 2, and 3 trials, typically in conjunction with Gallium-68 (68Ga) labeled Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) scans, to aid in the detection and staging of prostate carcinoma.[52]

Clinical Development and Research Landscape

The clinical development history of urea is a compelling example of how a long-established molecule can be continuously re-evaluated and repurposed for new therapeutic needs as medical science advances. Its journey has seen it fall out of favor for one indication (intracranial pressure) only to be "rediscovered" for another (hyponatremia), while simultaneously finding new life in supportive cancer care and diagnostics.

Overview of Completed Clinical Trials

Urea has been the subject of numerous clinical trials, demonstrating its versatility across different medical fields.

• Dermatology and Supportive Care:
• A completed Phase 4 trial (NCT00576550) successfully evaluated a moisturizing cream containing urea for the prevention of hand eczema recurrence.[54]
• In oncology supportive care, a Phase 3 trial (NCT02247830) investigated its use in managing and preventing radiodermatitis in patients with breast or head and neck cancer.[55]
• Another completed Phase 3 trial (NCT00296036) assessed a combination cream of urea and lactic acid for the prevention of hand-foot syndrome, a common side effect in patients receiving the chemotherapy agent capecitabine.[56]
• A Phase 2 trial (NCT04242927) for hand-foot skin reaction associated with VEGFR inhibitors has an unknown status.[57]
• Oncology Diagnostics:
• Urea has played a role in diagnostic protocols for prostate cancer. Completed Phase 2/3 trials (NCT02919111, NCT02918357) used it as part of a diagnostic regimen with 68Ga-PSMA-11 PET scans for initial staging and detection of biochemical recurrence.[53]
• A Phase 0 trial (NCT04282824) also included urea in a study examining factors that influence the biodistribution of 68Ga-PSMA-11 PET imaging agents.[52]

Current and Future Research Trajectories

Research into urea continues, with a focus on refining its existing applications and validating its efficacy with more robust clinical data.

• Systemic Use for Hyponatremia: A notable pilot study (NCT04588207) is currently underway to formally evaluate the safety, tolerability, and efficacy of oral urea for treating chronic hyponatremia in an outpatient setting. Importantly, this study aims to measure not only changes in serum sodium but also patient-centered outcomes like neurocognitive function and postural stability, which are known to be impaired in this condition.[58] This reflects a crucial shift toward generating high-quality evidence to support its broader use.
• Topical Use and Efficacy: Recent studies continue to reinforce the value of topical urea. An open-label clinical study published in 2023 demonstrated that a 20% urea cream significantly improved skin smoothness and texture in patients with keratosis pilaris.[59] A 2022 systematic review and meta-analysis concluded that urea-based moisturizers are superior to other types for improving skin hydration in patients with diabetes.[60] However, the landscape is not without nuance; a recent randomized controlled trial found that while a urea-based cream did not prevent the onset of capecitabine-associated hand-foot syndrome, it did show a trend toward lessening its ultimate severity.[61]

Table 3: Summary of Key Clinical Trials for Urea (DB03904)

ClinicalTrials.gov ID	Condition(s)	Phase	Purpose	Summary of Focus
NCT00576550	Hand Eczema	4	Prevention	Randomized trial of a moisturizing cream to prevent recurrence.54
NCT02247830	Radiodermatitis	3	Prevention	Management of radiodermatitis in patients with breast or head and neck cancer.55
NCT00296036	Hand-Foot Syndrome	3	Supportive Care	Use of pyridoxine and topical urea/lactic acid cream to prevent HFS in patients on capecitabine.56
NCT02919111	Prostate Cancer	2 / 3	Diagnostic	Use of 68Ga-PSMA-11 PET in intermediate to high-risk pre-prostatectomy patients.53
NCT04282824	Prostate Carcinoma	0	Diagnostic	Impact of monosodium glutamate on 68Ga-PSMA-11 PET imaging biodistribution.52
NCT04242927	Hand and Foot Skin Reaction	2	Supportive Care	Study of nicotinic acid on VEGFR inhibitor-associated hand-foot skin reactions.57

Formulations, Commercial Products, and Administration

Urea's versatility is reflected in the vast array of formulations and commercial products available to meet diverse clinical needs.

Topical Formulations

Urea is a ubiquitous ingredient in dermatological and cosmetic products.

• Formulation Types: It is formulated in numerous vehicles to suit different skin types and application sites, including creams, lotions, gels, foams, ointments, shampoos, and specialized nail lacquers or sticks.[19]
• Strengths and Concentrations: Commercial products are available in a wide spectrum of strengths, ranging from as low as 2% in daily moisturizers to as high as 50% in prescription-grade keratolytic or nail-debriding agents. The concentration is the primary determinant of the product's therapeutic effect, from hydrating to exfoliating.[16]
• Brand Names: The number of commercial products containing urea is extensive. Prominent brand names include Carmol (available in 10%, 20%, and 40% strengths), Keralac, Aquacare, Ureacin, Utopic, and Nutraplus. It is also a key ingredient in widely available consumer brands such as Eucerin, CeraVe, Cetaphil, and Gold Bond.[11]
• Combination Products: To achieve synergistic effects, urea is frequently co-formulated with other active ingredients. Common combinations include urea with alpha-hydroxy acids like lactic acid for enhanced exfoliation and hydration, with salicylic acid for keratolysis, with corticosteroids like hydrocortisone to reduce inflammation, or with various topical antibiotics.[38]

Systemic Formulations

Systemic formulations of urea are less common and are used for specific medical indications.

• Oral: For the management of hyponatremia, urea is available commercially as a powder for oral solution. A notable brand is Ure-Na, which is supplied in 15-gram sachets.[27] Compounding pharmacies can also prepare customized formulations, such as a 30% oral liquid, for patients who may have difficulty with the powder form.[30]
• Injectable (Historical): In the past, urea was available for intravenous infusion (e.g., brand name Ureaphil) for the reduction of intracranial pressure. An intra-amniotic injection was also used for pregnancy termination. These injectable formulations are now considered largely obsolete and have been replaced by alternatives with better safety profiles.[28]

Administration and Dosing

• Topical: For skin conditions, urea preparations are typically applied to the affected areas once or twice daily. Application to skin that is still damp after bathing is often recommended to maximize its hydrating effect.[21]
• Oral (for Hyponatremia): The typical dosage for treating hyponatremia ranges from 15 to 60 grams per day. The powder is usually mixed with 3 to 4 ounces of water or juice to improve palatability. The dose is titrated based on the patient's serum sodium response.[27]

Safety, Tolerability, and Risk Management

Adverse Effects Profile

Urea is generally considered to have a favorable safety profile, particularly in topical formulations.

• Topical: Topical urea is very well tolerated. The most frequently reported adverse effects are mild, transient, and localized to the site of application. These include stinging, burning, itching, or irritation.[14] These reactions are more common when using higher concentrations or when applying the product to sensitive, inflamed, or broken skin. Serious adverse reactions, such as blistering or signs of a skin infection, are rare.[63]
• Systemic: The primary adverse effect associated with oral urea for hyponatremia is its poor palatability, which can affect patient adherence.[44] Gastrointestinal upset has also been reported.[68] The main clinical risks of systemic use involve potential for fluid and electrolyte imbalances, which require careful monitoring.[68] The historical intravenous use of urea was associated with more severe complications, including coagulopathy, hemoglobinuria, and rebound intracranial pressure, which contributed to its replacement by mannitol.[29]

Contraindications and Precautions

• Topical: The primary contraindication for topical urea is a known hypersensitivity to urea or any of the inactive ingredients in a specific formulation.[21] It should not be applied near the eyes, lips, or mucous membranes. Over-the-counter labeling advises against use on irritated, infected, or open skin.[21] Caution should be exercised when applying high-concentration products to the feet of patients with compromised circulation or sensation, such as those with peripheral vascular disease or diabetes.[70]
• Systemic: Systemic urea is contraindicated in patients with severe renal impairment (anuria), severe dehydration, severe liver disease (due to the risk of ammonia accumulation), or active intracranial bleeding.[70] It is specifically contraindicated for the treatment of hypovolemic hyponatremia, where the primary issue is a deficit of both salt and water.[33]

Drug and Disease Interactions

• Systemic Urea: While there are over 60 documented drug interactions with systemic urea, most are classified as moderate or minor.[73] The more significant risks stem from disease interactions. Because urea acts as an osmotic diuretic, its use is contraindicated in patients with conditions that could be dangerously exacerbated by large fluid shifts. This includes patients with anuria, severe dehydration, pulmonary edema, or severe cardiac decompensation (a major interaction termed "fluid overload").[72] It should also be used with caution in patients with pre-existing renal or hepatic disease or diabetes due to the risk of inducing hyperosmolar states.[72]

Overdose and Toxicity

• Overdose with pharmaceutical-grade urea is exceptionally rare. The clinical syndrome of uremia, characterized by a toxic accumulation of endogenous urea and other nitrogenous waste products in the blood, is a consequence of end-stage kidney failure and is managed with dialysis or kidney transplantation, not as an acute poisoning.[76]
• Poisoning can occur from ingestion of related compounds, such as urea-based herbicides. These compounds are metabolized to aniline derivatives that can cause severe methemoglobinemia. Management is primarily supportive and symptomatic, and may require the administration of methylene blue as an antidote.[77]

Global Regulatory Status

Urea's long history of use and established safety profile have led to its widespread approval and availability worldwide, though its regulatory status varies by formulation and indication.

United States (FDA)

• Topical Products: In the U.S., urea-containing topical products are ubiquitous. Lower-strength formulations are widely available over-the-counter (OTC) in cosmetic and therapeutic skincare products.[11] Higher-strength preparations, such as 39% and 40% creams, are regulated as prescription (Rx-only) drugs.[21] The FDA has approved product labels for these high-strength creams, with recent effective dates in 2023.[79] These labels specify their indications for hyperkeratotic conditions and assign urea a Pregnancy Category B rating, indicating that animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.[21]
• Systemic Products: While urea itself is not approved as a standalone systemic drug for many indications, the FDA has approved several drugs that are directly related to the urea cycle. Olpruva was approved in 2022, and Ammonul was approved in 2005, both for the treatment of Urea Cycle Disorders (UCDs), which are genetic diseases affecting the body's ability to process ammonia into urea.[81]
• Diagnostic Devices: The FDA approved the PyloPlus UBT System in February 2020. This is a combination product consisting of 13C-urea and an analyzer for the non-invasive diagnosis of Helicobacter pylori infection.[51]

European Union (EMA)

The European Medicines Agency (EMA) oversees the scientific evaluation and authorization of medicinal products across the EU.[84] While specific EMA guidelines for urea as an active substance were not detailed in the available materials, the agency has approved related products and diagnostics.

• Urea Cycle Disorders: Ravicti (glycerol phenylbutyrate), a medicine used to manage UCDs by providing an alternative pathway for nitrogen waste removal, is authorized for use in the EU. It was granted orphan medicine designation in 2010 due to the rarity of the condition.[86] In 2022, a novel therapy based on allogeneic liver-derived stem cells also received orphan designation for the treatment of UCDs.[87]
• Diagnostics: Pylobactell, a 13C-urea breath test kit for diagnosing H. pylori infection, was granted a marketing authorization valid throughout the EU in 1998, demonstrating a long history of regulatory acceptance for this diagnostic application.[49]

Conclusion and Future Perspectives

Concluding Synthesis

Urea is a remarkable molecule that exemplifies the journey from a simple biological byproduct to a sophisticated, multi-modal therapeutic agent. Its historical significance, beginning with Wöhler's synthesis, is matched by its enduring clinical relevance. The compound's value is rooted in its favorable safety profile, low cost, and a unique duality of mechanisms. It acts through direct physicochemical properties as a humectant and osmotic agent, while also functioning as a biological response modifier, actively regulating gene expression to restore skin barrier integrity. This combination of passive and active effects makes it a uniquely effective and versatile tool in the medical armamentarium.

Emerging Applications and Research Frontiers

The clinical story of urea is still evolving, with research uncovering new potential applications.

• Anti-Aging and Preventative Dermatology: Urea's demonstrated ability to regulate epidermal genes, improve barrier function against irritants, and upregulate antimicrobial peptides suggests a promising future role in preventative dermatology and anti-aging skincare. Its application may expand beyond treating manifest skin diseases to proactively maintaining healthy, resilient skin and mitigating the signs of photodamage.[14]
• Oncology Drug Development: The urea functional group has been recognized by medicinal chemists as a "privileged scaffold." Its specific geometry and ability to act as both a hydrogen bond donor and acceptor make it ideal for establishing strong and specific interactions with biological targets. Consequently, the urea moiety has become a pivotal structural feature in the rational design of a new generation of targeted anticancer drugs, particularly kinase inhibitors such as Sorafenib and Lenvatinib.[88] This represents a sophisticated evolution from using urea as a drug itself to using its fundamental chemical structure as a blueprint for novel, highly potent therapeutics.

Unmet Needs and Future Directions

Despite its long history, key areas for future research remain.

• Systemic Use in Hyponatremia: While observational data and meta-analyses strongly support the use of oral urea for hyponatremia, there is a clear and frequently acknowledged need for large-scale, prospective, randomized controlled trials (RCTs). Such trials are essential to definitively establish its efficacy, define optimal dosing strategies, and directly compare its safety and effectiveness against current standards of care, such as vaptans.[32] The results of these trials will be critical for solidifying its place in international treatment guidelines.
• Molecular Dermatology: Further investigation into the precise molecular signaling pathways through which urea upregulates skin barrier genes could yield significant insights. Elucidating these mechanisms may uncover novel therapeutic targets for skin disease and could inspire the development of a new class of dermatological agents that mimic or enhance urea's beneficial biological effects on keratinocyte function.

Works cited

1. Urea | NH2CONH2 | CID 1176 - PubChem, accessed September 10, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Urea
2. Urea - Wikipedia, accessed September 10, 2025, https://en.wikipedia.org/wiki/Urea
3. Urea structure – CH 4 N 2 O - BYJU'S, accessed September 10, 2025, https://byjus.com/chemistry/urea/
4. Urea (chemical compound) | Research Starters - EBSCO, accessed September 10, 2025, https://www.ebsco.com/research-starters/science/urea-chemical-compound
5. Urea | Definition, Formula, Production, Uses, & Facts - Britannica, accessed September 10, 2025, https://www.britannica.com/science/urea
6. Urea - ECHEM, accessed September 10, 2025, https://echem-eg.com/2024/06/05/urea/
7. CAS Number 57-13-6 | EMPROVE Urea Beads, USP - Spectrum Chemical, accessed September 10, 2025, https://www.spectrumchemical.com/cas/57-13-6
8. Urea CAS#: 57-13-6 - ChemicalBook, accessed September 10, 2025, https://m.chemicalbook.com/ProductChemicalPropertiesCB5853861_EN.htm
9. Urea 57-13-6 | TCI AMERICA - Tokyo Chemical Industry, accessed September 10, 2025, https://www.tcichemicals.com/MX/en/p/U0073
10. Urea | 57-13-6 - ChemicalBook, accessed September 10, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5853861.htm
11. Urea-containing cream - Wikipedia, accessed September 10, 2025, https://en.wikipedia.org/wiki/Urea-containing_cream
12. Urea – applications, properties and significance in industry, accessed September 10, 2025, https://www.products.pcc.eu/en/blog/urea-applications-properties-and-significance-in-industry/
13. UREA CAS N°: 57-13-6, accessed September 10, 2025, https://hpvchemicals.oecd.org/UI/handler.axd?id=89564308-0887-4614-8a20-e542ce76221a
14. Urea in Dermatology: A Review of its Emollient, Moisturizing, Keratolytic, Skin Barrier Enhancing and Antimicrobial Properties - PMC, accessed September 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8611129/
15. Urea: A Clinically Oriented Overview from Bench to Bedside ..., accessed September 10, 2025, https://jddonline.com/articles/urea-a-clinically-oriented-overview-from-bench-to-bedside-S1545961616P0633X/
16. (PDF) Urea in Dermatology: A Review of its Emollient, Moisturizing, Keratolytic, Skin Barrier Enhancing and Antimicrobial Properties - ResearchGate, accessed September 10, 2025, https://www.researchgate.net/publication/355006704_Urea_in_Dermatology_A_Review_of_its_Emollient_Moisturizing_Keratolytic_Skin_Barrier_Enhancing_and_Antimicrobial_Properties
17. Urea in Dermatology: A Review of its Emollient, Moisturizing, Keratolytic, Skin Barrier Enhancing and Antimicrobial Properties | springermedizin.de, accessed September 10, 2025, https://www.springermedizin.de/urea-in-dermatology-a-review-of-its-emollient-moisturizing-kerat/19720124
18. Benefits of Urea for Skin Hydration - Flexitol, accessed September 10, 2025, https://flexitol.com/benefits-of-urea-for-skin-hydration/
19. Urea - DermNet, accessed September 10, 2025, https://dermnetnz.org/topics/urea
20. Topical urea in skincare: A review - PubMed, accessed September 10, 2025, https://pubmed.ncbi.nlm.nih.gov/30378232/
21. Urea Cream 40% - DailyMed, accessed September 10, 2025, https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ba6f162b-98ac-43a8-b098-ac08a428c91f
22. Urea Cream: Package Insert / Prescribing Information - Drugs.com, accessed September 10, 2025, https://www.drugs.com/pro/urea-cream.html
23. Urea (Topical) (Professional Patient Advice) - Drugs.com, accessed September 10, 2025, https://www.drugs.com/ppa/urea-topical.html
24. 6 Best Urea Creams & Lotions - Healthline, accessed September 10, 2025, https://www.healthline.com/health/psoriasis/urea-cream
25. Osmotic diuretic - Wikipedia, accessed September 10, 2025, https://en.wikipedia.org/wiki/Osmotic_diuretic
26. Therapeutic Uses of Diuretic Agents - StatPearls - NCBI Bookshelf, accessed September 10, 2025, https://www.ncbi.nlm.nih.gov/books/NBK557838/
27. Urea (Systemic) (Professional Patient Advice) - Drugs.com, accessed September 10, 2025, https://www.drugs.com/ppa/urea-systemic.html
28. Urea Monograph for Professionals - Drugs.com, accessed September 10, 2025, https://www.drugs.com/monograph/urea.html
29. The history of urea as a hyperosmolar agent to decrease brain ..., accessed September 10, 2025, https://www.researchgate.net/publication/261254425_The_history_of_urea_as_a_hyperosmolar_agent_to_decrease_brain_swelling
30. Urea 30% Oral Liquid - Customized for Your Needs - Bayview Pharmacy, accessed September 10, 2025, https://www.bayviewrx.com/formulas/Urea-30-Oral-Liquid-Oral-Hydration-Xerostomia-Oral-Mucositis-Sjogren-s-Syndrome-Dysphagia
31. Clinical factors associated with hyponatremia correction during treatment with oral urea - PMC - PubMed Central, accessed September 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11997808/
32. Clinical factors associated with hyponatremia correction during treatment with oral urea | Nephrology Dialysis Transplantation | Oxford Academic, accessed September 10, 2025, https://academic.oup.com/ndt/article/40/2/283/7715040
33. ure-Na (urea oral) dosing, indications, interactions, adverse effects, and more, accessed September 10, 2025, https://reference.medscape.com/drug/ure-na-urea-oral-4000378
34. Urea for the Treatment of Hyponatremia 2/2 SIADH: An Interview - AJKD Blog, accessed September 10, 2025, https://ajkdblog.org/2025/05/14/urea-for-the-treatment-of-hyponatremia-2-2-siadh-an-interview/
35. BUN and Creatinine - Clinical Methods - NCBI Bookshelf, accessed September 10, 2025, https://www.ncbi.nlm.nih.gov/books/NBK305/
36. 5. Pharmacokinetics and the Aging Process | ATrain Education, accessed September 10, 2025, https://www.atrainceu.com/content/5-pharmacokinetics-and-aging-process
37. Pharmacokinetic Studies of [14C] Urea (2); Absorption, Distribution, Metabolism and Excretion after Administration of [14C] Urea in Non-Fasted Rats | Request PDF - ResearchGate, accessed September 10, 2025, https://www.researchgate.net/publication/273195127_Pharmacokinetic_Studies_of_14CUrea_2_Absorption_Distribution_Metabolism_and_Excretion_after_Administration_of_14CUrea_in_Non-Fasted_Rats
38. Urea - brand name list from Drugs.com, accessed September 10, 2025, https://www.drugs.com/ingredient/urea.html
39. Urea-cream - Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Hepatic Dose | Drug Index, accessed September 10, 2025, https://www.pediatriconcall.com/drugs/urea-cream/1029
40. Clinical evidences of urea at high concentration on skin and annexes - ResearchGate, accessed September 10, 2025, https://www.researchgate.net/publication/347231051_Clinical_evidences_of_urea_at_high_concentration_on_skin_and_annexes
41. Urea Cream: Brands & Uses - Cleveland Clinic, accessed September 10, 2025, https://my.clevelandclinic.org/health/drugs/19302-urea-skin-cream-gel-lotion-ointment-or-nail-lacquer
42. Which Strength Urea Cream Should You Use? - The Foot Care Shop, accessed September 10, 2025, https://thefootcareshop.com.au/blogs/news/which-strength-urea-cream-should-you-use
43. The benefits and use of urea in skin care - Medical News Today, accessed September 10, 2025, https://www.medicalnewstoday.com/articles/urea-in-skincare
44. (PDF) Clinical efficacy of urea treatment in syndrome of inappropriate antidiuretic hormone secretion - ResearchGate, accessed September 10, 2025, https://www.researchgate.net/publication/361382216_Clinical_efficacy_of_urea_treatment_in_syndrome_of_inappropriate_antidiuretic_hormone_secretion
45. Urea to Treat Hyponatremia Due to Syndrome of Inappropriate Antidiuretic Hormone Secretion: A Systematic Review and Meta-Analysis - PubMed, accessed September 10, 2025, https://pubmed.ncbi.nlm.nih.gov/39362395/
46. Urea for management of the syndrome of inappropriate secretion of ..., accessed September 10, 2025, https://www.elsevier.es/en-revista-endocrinologia-nutricion-english-edition--412-articulo-urea-for-management-syndrome-inappropriate-S2173509314001561
47. Safety and Efficacy of Urea for Hyponatremia - PMC - PubMed Central, accessed September 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9125116/
48. Urea C-13: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 10, 2025, https://go.drugbank.com/drugs/DB09510
49. Pylobactell | European Medicines Agency (EMA), accessed September 10, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/pylobactell
50. Medical Uses of Urea - Bell Chem, accessed September 10, 2025, https://www.bellchem.com/news/medical-uses-of-urea
51. Premarket Approval (PMA) - FDA, accessed September 10, 2025, https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P170022
52. Urea Completed Phase 0 Trials for Prostate Carcinoma Diagnostic | DrugBank Online, accessed September 10, 2025, https://go.drugbank.com/drugs/DB03904/clinical_trials?conditions=DBCOND0028449&phase=0&purpose=diagnostic&status=completed
53. Urea Completed Phase 2 / 3 Trials for Prostate Cancer Diagnostic | DrugBank Online, accessed September 10, 2025, https://go.drugbank.com/drugs/DB03904/clinical_trials?conditions=DBCOND0062462&phase=2%2C3&purpose=diagnostic&status=completed
54. Urea Completed Phase 4 Trials for Hand Eczema Prevention | DrugBank Online, accessed September 10, 2025, https://go.drugbank.com/drugs/DB03904/clinical_trials?conditions=DBCOND0036264&phase=4&purpose=prevention&status=completed
55. Urea Completed Phase 3 Trials for Radiodermatitis Prevention | DrugBank Online, accessed September 10, 2025, https://go.drugbank.com/drugs/DB03904/clinical_trials?conditions=DBCOND0005427&phase=3&purpose=prevention&status=completed
56. Urea Completed Phase 3 Trials for Unspecified Adult Solid Tumor, Protocol Specific / Breast Cancer / Drug/Agent Toxicity by Tissue/Organ Supportive Care - DrugBank, accessed September 10, 2025, https://go.drugbank.com/drugs/DB03904/clinical_trials?conditions=DBCOND0028036%2CDBCOND0028489%2CDBCOND0028453&phase=3&purpose=supportive_care&status=completed
57. Hand and Foot Skin Reaction Unknown Status Phase 2 Trials for Urea (DB03904), accessed September 10, 2025, https://go.drugbank.com/indications/DBCOND0147027/clinical_trials/DB03904?phase=2&status=unknown_status
58. Study Details | NCT04588207 | Urea for Chronic Hyponatremia | ClinicalTrials.gov, accessed September 10, 2025, https://www.clinicaltrials.gov/study/NCT04588207
59. Evaluation of a Moisturizing Cream with 20% Urea for Keratosis Pilaris - JDDonline, accessed September 10, 2025, https://jddonline.com/articles/evaluation-of-a-moisturizing-cream-with-20-urea-for-keratosis-pilaris-S1545961624P1274X/
60. Systematic review and meta-analysis of the effectiveness of urea-based moisturizer on dry skin in diabetes melitus patients with - Journal of Pakistan Association of Dermatologists, accessed September 10, 2025, https://www.jpad.com.pk/index.php/jpad/article/download/1876/1734
61. Randomized controlled trial on the efficacy of topical urea-based cream in preventing capecitabine-associated hand-foot syndrome - PubMed Central, accessed September 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11831840/
62. Urea Topical Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed September 10, 2025, https://www.drugs.com/dosage/urea-topical.html
63. Urea: Side Effects, Uses, Dosage, Interactions, Warnings - Rx List, accessed September 10, 2025, https://www.rxlist.com/urea/generic-drug.htm
64. Products That Contain UREA || Skin Deep® Cosmetics Database | EWG, accessed September 10, 2025, https://www.ewg.org/skindeep/browse/ingredients/706791-UREA/
65. Urea (intravenous route) - Side effects & dosage - Mayo Clinic, accessed September 10, 2025, https://www.mayoclinic.org/drugs-supplements/urea-intravenous-route/description/drg-20066647
66. Urea Topical Side Effects: Common, Severe, Long Term - Drugs.com, accessed September 10, 2025, https://www.drugs.com/sfx/urea-topical-side-effects.html
67. New Study: American Formulation of Oral Urea Effective Treatment for Abnormally Low Blood Sodium Levels | National Kidney Foundation, accessed September 10, 2025, https://www.kidney.org/press-room/new-study-american-formulation-oral-urea-effective-treatment-abnormally-low-blood-sodium
68. Urea Side Effects: Common, Severe, Long Term - Drugs.com, accessed September 10, 2025, https://www.drugs.com/sfx/urea-side-effects.html
69. Urea (Systemic - Memorial Sloan Kettering Cancer Center, accessed September 10, 2025, https://www.mskcc.org/cancer-care/patient-education/medications/adult/urea-systemic
70. What are the contraindications of urea (carbamide)? - Dr.Oracle, accessed September 10, 2025, https://www.droracle.ai/articles/16802/contraindications-of-urea-
71. What are the interactions or contraindications of urea (40%) for chemical nail removal in patients with elevated urea levels, indicating Impaired renal function? - Dr.Oracle AI, accessed September 10, 2025, https://www.droracle.ai/articles/115131/urea-40-for-chemical-nail-removal-interactions-or-contraindications
72. Urea Disease Interactions - Drugs.com, accessed September 10, 2025, https://www.drugs.com/disease-interactions/urea.html
73. Urea Interactions Checker - Drugs.com, accessed September 10, 2025, https://www.drugs.com/drug-interactions/urea.html
74. Ure-Na Interactions Checker - Drugs.com, accessed September 10, 2025, https://www.drugs.com/drug-interactions/urea,ure-na.html
75. Ure-Na Disease Interactions - Drugs.com, accessed September 10, 2025, https://www.drugs.com/disease-interactions/urea,ure-na.html
76. Uremia: Causes, Symptoms, Diagnosis & Treatment - Cleveland Clinic, accessed September 10, 2025, https://my.clevelandclinic.org/health/diseases/21509-uremia
77. Poisoning due to urea herbicides - PubMed, accessed September 10, 2025, https://pubmed.ncbi.nlm.nih.gov/16390217/
78. Urea Fertilizer Poisoning-induced Multiorgan Failure: A Case Report, accessed September 10, 2025, https://apjmt.mums.ac.ir/article_23804_69f8cd20a0b5c7afb2bef1715dea1b5c.pdf
79. UREA - FDA Drug Approval Details - MedPath, accessed September 10, 2025, https://trial.medpath.com/drug/approvals/fda/78eb0598db643b8b
80. UREA 40% - FDA Drug Approval Details - MedPath, accessed September 10, 2025, https://trial.medpath.com/drug/approvals/fda/ed9322744142e1c0
81. FDA Approves Acer and Relief' Olpruva for Patients with Urea Cycle Disorders, accessed September 10, 2025, https://globalgenes.org/raredaily/fda-approves-acer-and-relief-olpruva-for-patients-with-urea-cycle-disorders/
82. Our History - National Urea Cycle Disorders Foundation, accessed September 10, 2025, https://nucdf.org/our-history.html
83. Ammonul (sodium benzoate and sodium phenylacetate) FDA Approval History - Drugs.com, accessed September 10, 2025, https://www.drugs.com/history/ammonul.html
84. European Medicines Agency - Wikipedia, accessed September 10, 2025, https://en.wikipedia.org/wiki/European_Medicines_Agency
85. The European regulatory system for medicines, accessed September 10, 2025, https://ecpc.org/wp-content/uploads/2019/08/ecpc-get-involved-EMA-the-european-regulatory-system-for-medicines-2.pdf
86. Ravicti | European Medicines Agency (EMA), accessed September 10, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/ravicti
87. EU/3/22/2685 - orphan designation for treatment of urea cycle disorders - EMA, accessed September 10, 2025, https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2685
88. Urea-based anticancer agents. Exploring 100-years of research with an eye to the future - Frontiers, accessed September 10, 2025, https://www.frontiersin.org/journals/chemistry/articles/10.3389/fchem.2022.995351/full
89. Recent advances in urea- and thiourea-containing compounds: focus on innovative approaches in medicinal chemistry and organic synthesis - PubMed Central, accessed September 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8293013/
90. Urea Derivatives in Modern Drug Discovery and Medicinal Chemistry - PMC - PubMed Central, accessed September 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7266097/